April 2024
1. FAIVRE A, de Seigneux S
   The role of hypoxia in chronic kidney disease: a nuanced perspective.
   Curr Opin Nephrol Hypertens. 2024 Apr 11. doi: 10.1097/MNH.0000000000000989.
   

   >> Share

   
   
2. HUISH S, Sinha S
   New therapeutic perspectives for vascular and valvular calcifications in chronic kidney disease.
   Curr Opin Nephrol Hypertens. 2024 Apr 5. doi: 10.1097/MNH.0000000000000985.
   

   >> Share

   
   March 2024
3. GOLDFARB DS
   Nephrologists should talk to their patients about climate change.
   Curr Opin Nephrol Hypertens. 2024;33:170-173.
   

   >> Share

   
   
4. ALEXIUK M, Tangri N
   Prediction models for earlier stages of chronic kidney disease.
   Curr Opin Nephrol Hypertens. 2024 Mar 1. doi: 10.1097/MNH.0000000000000981.
   

   >> Share

   
   February 2024
5. HOLLIDAY MW JR, Frost L, Navaneethan SD
   Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.
   Curr Opin Nephrol Hypertens. 2024 Feb 26. doi: 10.1097/MNH.0000000000000976.
   

   >> Share

   
   
6. HUNDEMER GL, Akbari A, Sood MM
   Has the time come for age-adapted glomerular filtration rate criteria to define chronic kidney disease: how soon is now?
   Curr Opin Nephrol Hypertens. 2024 Feb 26. doi: 10.1097/MNH.0000000000000971.
   

   >> Share

   
   January 2024
7. SPENCER A, Lavenburg LM, Sanders AP, Shah AD, et al
   Clearing the air: a review of the effects of air pollution on dialysis outcomes.
   Curr Opin Nephrol Hypertens. 2024 Jan 12. doi: 10.1097/MNH.0000000000000968.
   

   >> Share

   
   
8. DOBRE MA, Ahlawat S, Schelling JR
   Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives.
   Curr Opin Nephrol Hypertens. 2024 Jan 8. doi: 10.1097/MNH.0000000000000952.
   

   >> Share

   
   
9. RIZZOLO K, Shen JI
   Barriers to home dialysis and kidney transplantation for socially disadvantaged individuals.
   Curr Opin Nephrol Hypertens. 2024;33:26-33.
   

   >> Share

   
   
10. TAN SK, Pinzon-Cortes JA, Cooper ME
    Novel pharmacological interventions for diabetic kidney disease.
    Curr Opin Nephrol Hypertens. 2024;33:13-25.
    

    >> Share

    
    December 2023
11. MIRMOHAMMADALI SN, Gallant KMH, Biruete A
    Oh, My Gut! New insights on the role of the gastrointestinal tract and the gut microbiome in chronic kidney disease-mineral and bone disorder.
    Curr Opin Nephrol Hypertens. 2023 Dec 14. doi: 10.1097/MNH.0000000000000961.
    

    >> Share

    
    
12. BANSAL AD, Patel AA
    Dialysis initiation for patients with decompensated cirrhosis when liver transplant is unlikely.
    Curr Opin Nephrol Hypertens. 2023 Dec 4. doi: 10.1097/MNH.0000000000000959.
    

    >> Share

    
    November 2023
13. BISSINGER R, Qadri SM, Artunc F
    Eryptosis: a driver of anemia in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2023 Nov 22. doi: 10.1097/MNH.0000000000000957.
    

    >> Share

    
    
14. SPASIANO A, Benedetti C, Gambaro G, Ferraro PM, et al
    Predictive models in chronic kidney disease: essential tools in clinical practice.
    Curr Opin Nephrol Hypertens. 2023 Nov 9. doi: 10.1097/MNH.0000000000000950.
    

    >> Share

    
    
15. LUCAS B, Taal MW
    Blood pressure targets in chronic kidney disease: still no consensus.
    Curr Opin Nephrol Hypertens. 2023;32:497-501.
    

    >> Share

    
    October 2023
16. PHUA E, Shen Y
    The climate impact of dialysis.
    Curr Opin Nephrol Hypertens. 2023 Oct 30. doi: 10.1097/MNH.0000000000000940.
    

    >> Share

    
    August 2023
17. CASTLE EM, Billany RE, Lightfoot CJ, Annema C, et al
    Exercise as a therapeutic intervention in chronic kidney disease: are we nearly there yet?
    Curr Opin Nephrol Hypertens. 2023 Aug 24. doi: 10.1097/MNH.0000000000000923.
    

    >> Share

    
    June 2023
18. SINGH S
    Medication safety in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2023 Jun 9. doi: 10.1097/MNH.0000000000000907.
    

    >> Share

    
    May 2023
19. ALICIC RZ, Neumiller JJ, Tuttle KR
    Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2023 May 5. doi: 10.1097/MNH.0000000000000894.
    

    >> Share

    
    April 2023
20. KURO-O M
    Calcium phosphate microcrystallopathy as a paradigm of chronic kidney disease progression.
    Curr Opin Nephrol Hypertens. 2023 Apr 13. doi: 10.1097/MNH.0000000000000890.
    

    >> Share

    
    March 2023
21. LAFAVERS K, Garimella PS
    Uromodulin: more than a marker for chronic kidney disease progression.
    Curr Opin Nephrol Hypertens. 2023 Mar 10. doi: 10.1097/MNH.0000000000000885.
    

    >> Share

    
    February 2023
22. NAST CC
    Chronic kidney disease with unknown cause across the global spectrum.
    Curr Opin Nephrol Hypertens. 2023 Feb 10. doi: 10.1097/MNH.0000000000000874.
    

    >> Share

    
    January 2023
23. HANNA RM, Ahdoot RS, Rhee CM, Tantisattamo E, et al
    New and old approaches to nutritional management of acute and chronic glomerulonephritis.
    Curr Opin Nephrol Hypertens. 2023;32:76-80.
    

    >> Share

    
    
24. EDWARDS DP, Kalantar-Zadeh K, Streja E, Ahdoot RS, et al
    Practicing health equity in involuntary discharges to overcome disparities in dialysis and kidney patient care.
    Curr Opin Nephrol Hypertens. 2023;32:49-57.
    

    >> Share

    
    
25. FRIDELL JA, Stratta RJ
    Modern indications for referral for kidney and pancreas transplantation.
    Curr Opin Nephrol Hypertens. 2023;32:4-12.
    

    >> Share

    
    
26. TANTISATTAMO E, Hanna RM, Kalantar-Zadeh K
    Editorial: Innovations in multimodal and integrated approaches in kidney care and renal transplantation.
    Curr Opin Nephrol Hypertens. 2023;32:1-3.
    

    >> Share

    
    November 2022
27. ELDEHNI MT
    Frailty, multimorbidity and sarcopaenia in haemodialysis patients.
    Curr Opin Nephrol Hypertens. 2022;31:560-565.
    

    >> Share

    
    
28. PENNY JD, Moradshahi M, McIntyre CW
    Assessment of microcirculatory function during hemodialysis.
    Curr Opin Nephrol Hypertens. 2022;31:553-559.
    

    >> Share

    
    October 2022
29. NISSAISORAKARN V, Nissaisorakarn P, Kantachuvesiri S
    The current therapeutic approach for anaemia after kidney transplant.
    Curr Opin Nephrol Hypertens. 2022 Oct 12. pii: 00041552-990000000-00033.
    

    >> Share

    
    September 2022
30. POZO GARCIA L, Thomas SS, Rajesh H, Navaneethan SD, et al
    Progress in the management of patients with diabetes and chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022;31:456-463.
    

    >> Share

    
    
31. UPPAL NN, Corona A, Fishbane S
    Pruritus in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022;31:435-441.
    

    >> Share

    
    
32. ALI S, Navaneethan SD, Virani SS, Gregg LP, et al
    Revisiting diuretic choice in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022;31:406-413.
    

    >> Share

    
    August 2022
33. KULA A, Bansal N
    Applications of cardiac biomarkers in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022 Aug 5. pii: 00041552-990000000-00024.
    

    >> Share

    
    July 2022
34. TAAL MW
    Defining improvement in chronic kidney disease: regression and remission.
    Curr Opin Nephrol Hypertens. 2022 Jul 25. pii: 00041552-990000000-00023.
    

    >> Share

    
    
35. MARTIN A, Isakova T
    Editorial: Narrow the gap, build a bridge: an inspirational approach to chronic kidney disease-mineral and bone disorder.
    Curr Opin Nephrol Hypertens. 2022;31:303-305.
    

    >> Share

    
    June 2022
36. DUQUE EJ, Elias RM, Moyses RMA
    Phosphate balance during dialysis and after kidney transplantation in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022 Jun 13. pii: 00041552-990000000-00008.
    

    >> Share

    
    
37. AGORO R, White KE
    Anemia and fibroblast growth factor 23 elevation and chronic kidney disease: homeostatic interactions and emerging therapeutics.
    Curr Opin Nephrol Hypertens. 2022 Jun 13. pii: 00041552-990000000-00005.
    

    >> Share

    
    
38. SMOUT D, Jorgensen HS, Cavalier E, Evenepoel P, et al
    Clinical utility of bone turnover markers in patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022 Jun 13. pii: 00041552-990000000-00002.
    

    >> Share

    
    
39. DORR K, Kainz A, Oberbauer R
    Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease.
    Curr Opin Nephrol Hypertens. 2022 Jun 13. pii: 00041552-990000000-00001.
    

    >> Share

    
    March 2022
40. WEINHANDL ED
    The coronavirus disease 2019 pandemic: the disruptor that maintenance dialysis never anticipated.
    Curr Opin Nephrol Hypertens. 2022;31:185-190.
    

    >> Share

    
    February 2022
41. CANNEY M, Sood MM, Hundemer GL
    Contemporary risk prediction models in chronic kidney disease: when less is more.
    Curr Opin Nephrol Hypertens. 2022 Feb 25. pii: 00041552-900000000-98931.
    

    >> Share

    
    
42. TANGRI N, Ferguson TW
    Role of artificial intelligence in the diagnosis and management of kidney disease: applications to chronic kidney disease and acute kidney injury.
    Curr Opin Nephrol Hypertens. 2022 Feb 21. pii: 00041552-900000000-98932.
    

    >> Share

    
    
43. RAJ R
    Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2022 Feb 14. pii: 00041552-900000000-98934.
    

    >> Share

    
    
44. TAN H, Xu J, Liu Y
    Ageing, cellular senescence and chronic kidney disease: experimental evidence.
    Curr Opin Nephrol Hypertens. 2022 Feb 9. pii: 00041552-900000000-98935.
    

    >> Share

    
    January 2022
45. MUREA M, Flythe JE, Anjay R, Emaad AM, et al
    Kidney dysfunction requiring dialysis is a heterogeneous syndrome: we should treat it like one.
    Curr Opin Nephrol Hypertens. 2022;31:92-99.
    

    >> Share

    
    
46. SUMIDA K, Lau WL, Kalantar-Zadeh K, Kovesdy CP, et al
    Novel intestinal dialysis interventions and microbiome modulation to control uremia.
    Curr Opin Nephrol Hypertens. 2022;31:82-91.
    

    >> Share

    
    
47. TANTISATTAMO E, Hanna RM, Kalantar-Zadeh K
    Editorial: Novel therapeutic approaches in chronic kidney disease and kidney transplantation: the draw of evolving integrated multimodal approaches in the targeted therapy era.
    Curr Opin Nephrol Hypertens. 2022;31:1-5.
    

    >> Share

    
    December 2021
48. BLEYER AJ
    Factors that lead to dialysis as the preferred treatment modality for patients with chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 Dec 24. pii: 00041552-900000000-98940.
    

    >> Share

    
    
49. LEON SJ, Tangri N
    Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
    Curr Opin Nephrol Hypertens. 2021 Dec 24. pii: 00041552-900000000-98941.
    

    >> Share

    
    November 2021
50. OTOBE Y, Rhee CM, Nguyen M, Kalantar-Zadeh K, et al
    Current status of the assessment of sarcopenia, frailty, physical performance and functional status in chronic kidney disease patients.
    Curr Opin Nephrol Hypertens. 2021 Nov 11. pii: 00041552-900000000-98950.
    

    >> Share

    
    
51. AHDOOT RS, Kalantar-Zadeh K, Burton JO, Lockwood MB, et al
    Novel approach to unpleasant symptom clusters surrounding pruritus in patients with chronic kidney disease and on dialysis therapy.
    Curr Opin Nephrol Hypertens. 2021 Nov 8. pii: 00041552-900000000-98960.
    

    >> Share

    
    
52. KALANTAR-ZADEH K, Rhee CM, Joshi S, Brown-Tortorici A, et al
    Medical nutrition therapy using plant-focused low-protein meal plans for management of chronic kidney disease in diabetes.
    Curr Opin Nephrol Hypertens. 2021 Nov 8. pii: 00041552-900000000-98952.
    

    >> Share

    
    
53. TANTISATTAMO E, Hamiduzzaman A, Sohn P, Ahdoot R, et al
    Reconciling Systolic Blood Pressure Intervention Trial with Eighth Joint National Commission: a nuanced view of optimal hypertension control in the chronic kidney disease population.
    Curr Opin Nephrol Hypertens. 2021 Nov 5. pii: 00041552-900000000-98955.
    

    >> Share

    
    
54. TANTISATTAMO E, Kalantar-Zadeh K, Molnar MZ
    Nutritional and dietary interventions to prolong renal allograft survival after kidney transplantation.
    Curr Opin Nephrol Hypertens. 2021 Nov 5. pii: 00041552-900000000-98954.
    

    >> Share

    
    
55. RHEE CM, Kalantar-Zadeh K, Tuttle KR
    Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease.
    Curr Opin Nephrol Hypertens. 2021 Nov 5. pii: 00041552-900000000-98953.
    

    >> Share

    
    
56. ALSAAD R, Chen X, McAdams-DeMarco M
    The clinical application of frailty in nephrology and transplantation.
    Curr Opin Nephrol Hypertens. 2021;30:593-599.
    

    >> Share

    
    
57. STEWART P, Stewart J
    Noninvasive continuous intradialytic blood pressure monitoring: the key to improving haemodynamic stability.
    Curr Opin Nephrol Hypertens. 2021;30:559-562.
    

    >> Share

    
    July 2021
58. SINHA S, Raggi P, Chertow GM
    SNF472: mechanism of action and results from clinical trials.
    Curr Opin Nephrol Hypertens. 2021;30:424-429.
    

    >> Share

    
    November 2020
59. TANTISATTAMO E, Kalantar-Zadeh K, Halleck F, Duettmann W, et al
    Novel approaches to sarcopenic obesity and weight management before and after kidney transplantation.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000673.
    

    >> Share

    
    
60. ONG SC, Rhee CM
    Novel management of diabetes in kidney transplantation.
    Curr Opin Nephrol Hypertens. 2020 Nov 12. doi: 10.1097/MNH.0000000000000665.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share